Opendata, web and dolomites


Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Total Cost €


EC-Contrib. €






 ECRC project word cloud

Explore the words cloud of the ECRC project. It provides you a very rough idea of what is the project "ECRC" about.

validation    understand    justified    urgency    list    nature    priorities    aligned    cfp3ii    rapid    efficacy    lacking    ec    countries    meet    feasible    virus    fda    efforts    ll    strengthen    outbreaks    lot    launch    risks    mechanism    action    cfp    progression    relates    standard    generating    encouraged    agree    2019    licensure    regulatory    public    calls    remaining    sga    ema    middle    blueprint    chikungunya    gaps    cepi    accelerate    grant    eligibility    income    stage    fever    market    regulations    identification    structured    timing    criteria    interim    cfp3i    context    sub    pipeline    vaccine    chik    align    promise    2018    despite    mitigate    deemed    launched    pathogens    clinical    ebola    afforded    entities    valley    duly    outbreak    benefit    quite    approval    evd    protective    mature    inherently    launching    co    chikv    proposals    unpredictable    stated    leverage    rift    candidates    cfp3    few    january    risk    investments    rvf    protection    mid    emergencies    advantage    vaccines    incentives    health    humans    scope    award    rvfv    correlates    diseases   

Project "ECRC" data sheet

The following table provides information about the project.


Organization address
city: OSLO
postcode: 473
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 51˙428˙572 €
 EC max contribution 36˙000˙000 € (70%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SGA-SC1-CEPI-2019
 Funding Scheme SGA-CSA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

The objective of this specific grant agreement (SGA) is to leverage co-funding from the European Commission to accelerate the development of vaccines against Rift Valley Fever (RVF), Chikungunya (CHIK) and Ebola virus diseases (EVD).

• RVF and CHIK vaccine development will be addressed by CEPI’s third Call for Proposals (CFP3), and it will structured through launching two sub-calls; CFP3i and CFP3ii. This SGA only relates to CFP3i, and has the following objectives: a) For RVFV vaccines, to support clinical testing or activities enabling clinical Phase l/ll testing of the most advanced RVFV candidates, including identification of correlates of protection and their validation, which can facilitate future regulatory approval. b) For CHIKV vaccines, to support the rapid progression of the most advanced clinical CHIKV vaccine candidates through mid-stage and late-stage clinical development, and to support activities enabling future efficacy testing, including identification of correlates of protection and their validation that can facilitate future regulatory approval. The call will be launched January 2019 and will be open to all entities that meet the eligibility criteria and agree to CEPI’s award conditions – which are aligned with EU regulations.

EVD vaccine development will focus on addressing the remaining evidence gaps towards the licensure by FDA and/or EMA of the leading vaccine candidates, particularly on generating evidence of the protective efficacy of the vaccines in humans in the context of an outbreak. Towards this scope, and in order to take advantage of the research opportunities afforded by any large-scale Ebola outbreak, CEPI is expected to facilitate the rapid launch of clinical studies of the lead Ebola vaccine candidates. If feasible, the standard CfP mechanism will be used. However, in duly justified emergencies CEPI may award a grant without a call for proposals.

RVF and EVD are included among the WHO R&D Blueprint list of priority pathogens in 2018, while CHIKV was deemed to present a major public health risks for which “further research and development is needed” and “efforts in the interim to understand and mitigate them are encouraged”. Despite this stated urgency, action has been lacking – in part because low and middle-income countries are most at risk for future outbreaks and market incentives are lacking, both due to this and the inherently unpredictable nature and timing of future outbreaks. The current pipeline of candidates for these three pathogens does however bring a lot of promise; since there are quite a few mature candidates in the pipeline, targeted investments from CEPI and the EC could bring significant benefit and further strengthen and align the two entities’ existing priorities in vaccine development.


List of deliverables.
Opening of call online Documents, reports 2020-02-12 15:34:46
Project description template Documents, reports 2020-02-12 15:34:36

Take a look to the deliverables list in detail:  detailed list of ECRC deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ECRC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ECRC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

HEAP (2020)

Human Exposome Assessment Platform

Read More